TY - JOUR
T1 - Proceedings From the Global Cardio-Oncology Summit
T2 - The Top 10 Priorities to Actualize for CardioOncology
AU - Lenihan, Daniel J.
AU - Fradley, Michael G.
AU - Dent, Susan
AU - Brezden-Masley, Christine
AU - Carver, Joseph
AU - Filho, Roberto Kalil
AU - Neilan, Tomas G.
AU - Blaes, Anne
AU - Melloni, Chiara
AU - Herrmann, Joerg
AU - Armenian, Saro
AU - Thavendiranathan, Paaladinesh
AU - Armstrong, Gregory T.
AU - Ky, Bonnie
AU - Hajjar, Ludhmila
N1 - Publisher Copyright:
© 2019 The Authors
PY - 2019/12
Y1 - 2019/12
N2 - The discipline of cardio-oncology has expanded at a remarkable pace. Recent developments and challenges to clinicians who practice cardio-oncology were presented at the Global Cardio-Oncology Summit on October 3 to 4, 2019, in São Paulo, Brazil. Here, we present the top 10 priorities for our field that were discussed at the meeting, and also detail a potential path forward to address these challenges. Defining robust predictors of cardiotoxicity, clarifying the role of cardioprotection, managing and preventing thromboembolism, improving hematopoietic stem cell transplant outcomes, personalizing cardiac interventions, building the cardio-oncology community, detecting and treating cardiovascular events associated with immunotherapy, understanding tyrosine kinase inhibitor cardiotoxicity, and enhancing survivorship care are all priorities for the field. The path forward requires a commitment to research, education, and excellence in clinical care to improve our patients' lives.
AB - The discipline of cardio-oncology has expanded at a remarkable pace. Recent developments and challenges to clinicians who practice cardio-oncology were presented at the Global Cardio-Oncology Summit on October 3 to 4, 2019, in São Paulo, Brazil. Here, we present the top 10 priorities for our field that were discussed at the meeting, and also detail a potential path forward to address these challenges. Defining robust predictors of cardiotoxicity, clarifying the role of cardioprotection, managing and preventing thromboembolism, improving hematopoietic stem cell transplant outcomes, personalizing cardiac interventions, building the cardio-oncology community, detecting and treating cardiovascular events associated with immunotherapy, understanding tyrosine kinase inhibitor cardiotoxicity, and enhancing survivorship care are all priorities for the field. The path forward requires a commitment to research, education, and excellence in clinical care to improve our patients' lives.
KW - anthracycline
KW - antiangiogenic therapy
KW - bone marrow transplantation
KW - breast cancer
KW - cancer survivorship
KW - immunotherapy
KW - thrombosis
KW - tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85085291624&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085291624&partnerID=8YFLogxK
U2 - 10.1016/j.jaccao.2019.11.007
DO - 10.1016/j.jaccao.2019.11.007
M3 - Review article
AN - SCOPUS:85085291624
SN - 2666-0873
VL - 1
SP - 256
EP - 272
JO - JACC: CardioOncology
JF - JACC: CardioOncology
IS - 2
ER -
